Professor Peter John Meikle
Baker Heart and Diabetes Institute, Melbourne (Australia)
Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention
Event: ESC Congress 2018
Topic: Lipid-Lowering Agents
Session: Cardiovascular risk and its modification
ESC 365 is supported by
